Executive Summary / Key Takeaways
-
The "Third Act" AI Transformation: Doximity is leveraging its dominant physician network (85%+ of U.S. doctors) to launch what management calls its "third act"—AI tools like DoxGPT and Scribe that address physician burnout and information overload, with over 300,000 prescribers already using these tools despite zero revenue contribution in guidance, positioning for a potential revenue inflection later in calendar 2026.
-
Policy Headwinds Creating Temporary Disruption: "Most Favored Nation" agreements between pharma companies and the White House have created client uncertainty, delaying deals and pushing revenue into later quarters, resulting in Q4 FY26 guidance of 4% growth—yet management believes this represents a timing shift, not demand destruction, with unreleased budgets likely deploying later in the year.
-
Core Business Resilience Amid Uncertainty: Despite policy challenges, underlying engagement metrics remain at all-time highs—over 1 million quarterly active prescribers in the newsfeed, 720,000 workflow tool users (largest sequential gain ever), and 112% net revenue retention—demonstrating that Doximity's value proposition remains intact even if purchasing patterns have temporarily shifted.
-
Financial Fortress Enables Strategic Investment: With $735 million in cash and marketable securities, 60% adjusted EBITDA margins, and $58.5 million in quarterly free cash flow, Doximity has the firepower to aggressively invest in AI infrastructure while repurchasing $196.8 million in shares during Q3 alone, providing downside protection during the policy-induced slowdown.
-
The Critical Variable: The investment thesis hinges on whether policy uncertainty resolves by mid-2026, allowing delayed pharma budgets to deploy, and whether Doximity can successfully commercialize its AI suite—two factors that will determine whether this is a temporary 4% growth quarter or the start of a more concerning trend.
Setting the Scene: The Physician Platform That Became Essential Infrastructure
Founded in April 2010 and headquartered in San Francisco, Doximity began as the "LinkedIn for doctors" but evolved into something far more integral to U.S. healthcare delivery. The company built its foundation on network effects, achieving what no competitor has replicated: direct access to over 85% of all U.S. physicians and two-thirds of all nurse practitioners and physician assistants. This was the result of a deliberate strategy to become the digital home for medical professionals, offering news, collaboration tools, career management, and eventually workflow solutions like telehealth and digital fax.
The business model is powerful. Doximity generates approximately 95% of its revenue from subscription-based services sold to pharmaceutical companies and health systems. These customers pay for targeted access to Doximity's exclusive physician network through three core solutions: Marketing Solutions (sponsored content and targeted outreach), Hiring Solutions (recruitment tools), and Workflow Solutions (telehealth, scheduling, and now AI tools). The remaining 5% comes from temporary staffing through its Curative acquisition. This subscription-heavy model creates predictable revenue streams and has delivered gross margins of 89.75% and operating margins of 38.89% over the trailing twelve months.
What makes this positioning defensible is the multi-sided network effect. As more physicians join the platform, pharma companies get better targeting and ROI, which funds more features for physicians, which attracts more physicians, which makes the platform more valuable to health systems. This flywheel has created a moat that competitors like Teladoc (TDOC), American Well (AMWL), and even LinkedIn (MSFT) have failed to cross. While Teladoc focuses on patient-facing telehealth and American Well struggles with enterprise telehealth infrastructure, Doximity owns the physician relationship—the most valuable and hardest-to-reach constituency in healthcare.
The industry context makes this positioning increasingly valuable. Physician burnout has reached crisis levels, with doctors spending an average of 1.5 hours nightly on "pajama time" documentation. Meanwhile, pharmaceutical companies face pressure to demonstrate ROI on every marketing dollar, pushing them toward digital channels that can prove performance. The digital pharma advertising market is growing at roughly 5% annually, and Doximity has consistently grown at roughly twice the market rate by capturing share from less measurable channels. This sets the stage for Doximity's most ambitious move yet: transforming from a marketing platform into an AI-powered clinical workflow essential.
Technology, Products, and Strategic Differentiation: The "Third Act" AI Suite
Doximity's product evolution reveals a deliberate progression from engagement to utility to intelligence. The "newsfeed" and "LinkedIn-style" features formed the initial core, creating habit formation and network density. Workflow tools like scheduling, digital fax, and the Doximity Dialer telehealth platform (which conducts over 300,000 voice and video visits on an average weekday) transformed the platform from a social network into a daily utility. The Dialer has been ranked the #1 Best in KLAS Telehealth Video Platform for five consecutive years, with pickup rates three times higher than competitors because it avoids being marked as spam—a detail that matters enormously for physician adoption.
Now comes the "third act": AI tools designed to address the two biggest pain points in modern medicine—information overload and documentation burden. Doximity GPT, launched in April/May 2025 as the first HIPAA-compliant physician AI, and Doximity Scribe, an ambient notetaking tool launched in late July/early August 2025, represent a fundamental expansion of the platform's value proposition. The July 2025 acquisition of Pathway Medical for $63 million accelerated this vision, bringing a medical AI dataset and models that scored 96% on the U.S. medical licensing exam, outperforming competitors.
The significance lies in the fact that these tools are already showing remarkable traction before generating a dollar of revenue. Over 300,000 unique prescribers used Doximity's AI products in Q3 FY26, querying DoxGPT an average of four times per week in January. Scribe users nearly tripled from Q1 to Q2 FY26, with over 75% returning weekly—a retention rate that signals genuine utility. More than 100 health systems representing over 180,000 prescribers have already purchased the AI suite, clearing privacy and AI committees to allow patient data into these secure tools.
The competitive differentiation is stark. Doximity's AI is the only medical AI with a built-in deterministic drug reference , addressing a critical weakness of large language models that struggle with drug information and dosages. It's also the only medical AI providing full PDF access to over 2,000 medical journals. But the most important differentiator is the "peer check" program—over 10,000 U.S. physician experts reviewing clinical answers to build trust. This editorial board addresses the top concern of 71% of physicians who cite accuracy and reliability as their primary AI worry, especially after a Stanford Harvard study found AI can cause clinical harm in up to 22% of real patient cases.
The cost structure reinforces the opportunity. Management stated the cost of delivering Scribe service is "pennies per visit," similar to Dialer, due to reduced transcription and LLM costs. This means that when Doximity does commercialize these tools—expected later in calendar 2026—the margin expansion potential is substantial. The company is explicitly following the Dialer playbook: launch as a free product to drive adoption, prove value, then convert to enterprise revenue. With over 300,000 active users already, the foundation is being laid for what could become a nine-figure business.
Financial Performance: Evidence of a Resilient Core
Doximity's Q3 FY26 results demonstrate a company navigating temporary headwinds while maintaining exceptional profitability. Revenue of $185.05 million grew 10% year-over-year, beating guidance by 2%, while adjusted EBITDA of $111.4 million delivered a 60% margin—7% above guidance. This 60% EBITDA margin, combined with 91% non-GAAP gross margins, places Doximity in rare company among healthcare technology platforms. For context, Teladoc operates at negative operating margins and American Well at negative operating margins, while even high-growth Tempus AI (TEM) runs at negative operating margins. Doximity's profitability is structural.
The revenue composition reveals both strength and vulnerability. Subscription revenue of $175.38 million represents 95% of total revenue, providing predictability. The pharma business is Doximity's fastest-growing segment, with average revenue per existing Marketing Solutions customer up 7% in Q3 and 13% over nine months. However, the net revenue retention rate of 112% signals that policy uncertainty is impacting expansion rates. For the top 20 customers, NRR was 117%, and these customers account for 84% of total revenue—a concentration that amplifies both the impact of policy delays and the upside when budgets release.
The segment dynamics show a strategic shift toward integrated offerings. Multi-module integrated programs represented over 40% of bookings in Q2 FY26, up from less than 5% a year ago. These AI-optimized programs launch in January, allowing clients to evaluate results sooner and make incremental buying decisions more consistently. This matters because it's transforming Doximity's revenue curve from seasonal to more predictable, while also delivering higher ROI for clients. The client portal is accelerating this shift—quarterly active client users are up 3x year-over-year, and ROI studies shown to clients are up over 10x, fueling interest in AI-powered automation.
Cash generation remains robust. Q3 FY26 free cash flow of $58.5 million and nine-month operating cash flow of $273.26 million demonstrate that the business converts profits to cash efficiently. With $735.1 million in cash and marketable securities and essentially no debt, Doximity has the balance sheet flexibility to invest through the policy uncertainty. This financial strength enabled $196.8 million in share repurchases during Q3, with the board approving a new $500 million authorization in February 2026. Management expects dilution from new awards to be more than offset by buybacks, signaling confidence in valuation.
The cost structure reveals AI investment accelerating. Research and development expense increased 54% in Q3, driven by $9.7 million in stock-based compensation from new awards for the AI team. Gross margin compressed slightly to 91% from 93% due to AI infrastructure investments. These investments are necessary to support the 5x year-over-year growth in AI tool usage. The company expects AI infrastructure costs to rise in the back half of FY26, yet still targets 50%+ annual EBITDA margins, highlighting the inherent operating leverage in the model.
Outlook, Guidance, and Execution Risk
Management's guidance tells a story of cautious optimism amid uncertainty. Q4 FY26 revenue guidance of $143-144 million implies 4% growth at the midpoint—a deceleration from Q3's 10% and Q2's 23%. Adjusted EBITDA margin guidance of 45% also represents a step-down from Q3's 60%, reflecting both revenue mix and increased AI investment. For the full FY26, revenue guidance of $642.5-643.5 million (13% growth) and 55% EBITDA margins suggest management expects a stronger second half, but the Q4 guide indicates that recovery hasn't started yet.
The assumptions behind this guidance reveal management's thinking. The operating assumption is that the pharma HCP digital market will grow roughly 5% in calendar 2026, down from the 5-7% range assumed earlier. This reflects the policy uncertainty, particularly the 16 of top 20 pharma companies signing most favored nation agreements focused on tariffs and pricing between late December and early January. These agreements have delayed deals that normally close by December 31, pushing them into fiscal Q4 and beyond. However, management believes these are timing shifts, not demand shifts, with unreleased funds likely becoming available during the upsell season later in the year.
The AI commercialization timeline is the critical swing factor. Management explicitly stated that no revenue upside from AI is included in current guidance, with commercial AI products expected in market later in calendar 2026. This creates potential asymmetry: if AI tools launch successfully and tap into innovation upsell budgets (which represent 55% of digital marketing spend in healthcare), revenue could accelerate beyond guidance. The company is targeting search budgets, which represent a large new TAM, and believes its integrated programs will become the vast majority of the business, offering better predictability.
Execution risk centers on two factors. First, can Doximity maintain its competitive moat while scaling AI? The Pathway acquisition integration has been fast—full dataset integration in 7 weeks—but the "peer check" program requires ongoing physician engagement. Second, will policy uncertainty resolve as expected? Health systems are typically more near-term impacted by policy changes, so guidance doesn't assume continued momentum there. If MFN agreements create structural rather than temporary budget changes, the recovery could be delayed into FY27.
Risks and Asymmetries: What Could Break the Thesis
The most immediate risk is policy uncertainty extending beyond mid-2026. While management frames MFN agreements as a timing issue, these deals could fundamentally alter pharma marketing budgets if pricing pressures intensify. The fact that 84% of revenue comes from 126 customers spending over $500K annually creates concentration risk—if even a few large pharma clients restructure their digital spend, growth could disappoint for multiple quarters. This is particularly concerning given that fiscal 2025 benefited from a strategic shift to multi-module integrated offerings that pulled revenue forward, creating tougher comparisons for fiscal 2026.
AI accuracy concerns represent a longer-term existential risk. Despite Doximity's peer check system and built-in drug reference, the underlying technology faces scrutiny. A recent Stanford Harvard study found AI can cause clinical harm in up to 22% of real patient cases, and management has candidly stated that no AI has eliminated mistakes. While Doximity's deterministic drug reference and physician oversight differentiate it from general-purpose LLMs, any high-profile clinical error involving its tools could severely damage the trusted brand that underpins the entire business model. The ongoing lawsuit from OpenEvidence Inc., alleging unauthorized access to an AI medical information platform, adds legal risk that could delay AI commercialization.
Revenue concentration in pharma marketing creates vulnerability to cyclical spending cuts. While Doximity has diversified into hiring solutions and workflow tools, approximately 70% of revenue still derives from pharmaceutical marketing budgets. In an efficiency-focused environment, these budgets are scrutinized intensely. If macroeconomic conditions worsen or drug pricing reform accelerates, Doximity's high-margin revenue could face pressure that its AI tools aren't yet ready to offset. The company's SMB customer base, while growing bookings at 100% year-over-year, remains a small portion of total revenue.
Competitive dynamics pose a nuanced threat. While Doximity dominates physician networking, Tempus AI is growing revenue at 83% year-over-year by focusing on precision medicine AI, albeit with negative profit margins. If Tempus or other well-funded competitors successfully broaden into general clinical reference tools, they could erode Doximity's differentiation. More concerning is the risk of commoditization—if general LLMs improve sufficiently on medical knowledge, the value of Doximity's specialized platform could diminish, though the peer check system and HIPAA compliance would remain differentiators.
Competitive Context: Why Doximity's Positioning Is Unique
Comparing Doximity to named competitors reveals structural advantages that extend beyond growth rates. Teladoc operates at negative operating margins with $1.5 billion in debt, while Doximity runs at 38.9% operating margins with net cash. Teladoc's patient-facing telehealth model requires massive scale to achieve profitability, whereas Doximity's physician-focused tools generate high margins at lower scale because they command premium pricing from pharma clients seeking measurable ROI. Doximity's network effects—where each additional physician makes the platform more valuable to all customers—create a moat that Teladoc's more transactional telehealth visits cannot replicate.
American Well presents a cautionary tale. With negative operating margins and declining revenue, Amwell's enterprise telehealth platform has struggled to achieve scale or profitability. Doximity's workflow tools, by contrast, have reached 720,000 quarterly active users with the largest sequential gain ever in Q3 FY26. The difference lies in product-market fit: Doximity solves daily physician pain points that create habitual engagement, while Amwell's platform requires enterprise-wide adoption decisions that face IT procurement friction.
Tempus AI represents the growth threat, with 83% revenue growth driven by AI-driven precision medicine. However, Tempus operates at negative operating margins and negative return on equity, reflecting massive R&D investment and cash burn. Doximity's AI strategy is more capital-efficient, leveraging its existing physician network for distribution rather than building from scratch. While Tempus may win in specialized oncology AI, Doximity's generalist approach—addressing the daily questions and documentation burden of all physicians—targets a larger TAM with better unit economics.
The competitive moats extend beyond financial metrics. Doximity's 10,000 peer check experts exceed the largest players in the industry. The built-in deterministic drug reference addresses a known LLM weakness regarding hallucinations. These are trust-building mechanisms that create switching costs. Once a health system has cleared Doximity's AI tools through privacy and AI committees—a process that over 100 systems have completed—ripping them out requires repeating that costly review process.
Valuation Context: Pricing a Profitable Platform in Transition
At $25.03 per share, Doximity trades at 21.03x trailing earnings and 15.34x price-to-free-cash-flow—multiples that appear reasonable for a profitable, growing software platform but must be evaluated against the policy headwinds and AI investment cycle. The EV/Revenue multiple of 6.25x sits between Tempus AI's 7.36x and Teladoc's 0.49x. This positioning reflects the market's uncertainty: is Doximity a mature, slower-growth platform deserving of a value multiple, or an AI-transforming growth story commanding a premium?
The balance sheet strength justifies patience. With $735 million in cash and essentially no debt, Doximity has over 12 years of runway at current burn rates even if profitability temporarily declines. This financial fortress enabled $196.8 million in Q3 share repurchases—nearly 4% of the current market cap in a single quarter—at an average price that management clearly viewed as attractive. The new $500 million authorization signals continued confidence.
Cash flow metrics tell a more complete story than earnings multiples. The 14.94x price-to-operating-cash-flow ratio reflects the company's ability to convert 37.54% profit margins into actual cash, a contrast to competitors burning cash. The 23.82% return on equity, supported by the 12.84% return on assets, demonstrates that AI investments are generating productive returns rather than destructive dilution. Management expects stock-based compensation to increase to high teens as a percentage of revenue in FY26-27 due to Pathway acquisition and AI team grants, then trend back to mid-teens by 2028, suggesting this is a temporary investment phase rather than permanent dilution.
Valuation must be weighed against the AI optionality. With no AI revenue in guidance, the current price reflects only the core marketing and workflow business growing at mid-single digits due to policy uncertainty. If Doximity successfully commercializes its AI suite and captures even a portion of the healthcare search market, the revenue multiple would compress rapidly. Conversely, if policy headwinds persist and AI commercialization stalls, the 21x P/E could prove expensive for a 4-5% grower. The asymmetry favors patient investors who believe the policy overhang is temporary and AI monetization is probable.
Conclusion: A Dominant Platform at an Inflection Point
Doximity stands at a critical juncture where near-term policy uncertainty masks the early stages of what could be a transformative AI expansion. The company's core business—connecting pharmaceutical companies to 85% of U.S. physicians through a trusted, high-ROI platform—remains healthy, as evidenced by record engagement metrics, 91% gross margins, and robust cash generation. The 112% net revenue retention, while down from prior quarters, reflects delayed budget deployments rather than customer churn or competitive displacement.
The "third act" AI strategy represents Doximity's most ambitious expansion yet. By acquiring Pathway Medical and building a peer-reviewed AI suite that already serves 300,000 prescribers, the company is positioning to capture a massive new market in clinical decision support and documentation automation. The fact that over 100 health systems have already purchased access for 180,000 prescribers before commercial launch suggests strong latent demand. If Doximity can execute on its plan to launch commercial AI products later in calendar 2026, it could tap into innovation budgets and search spending that represent a multi-billion dollar TAM expansion.
The risk/reward profile is defined by timing. If policy headwinds from MFN agreements persist beyond mid-2026, the core business could face multiple quarters of sub-5% growth, pressuring the valuation multiple. If AI commercialization is delayed or encounters clinical accuracy issues, the growth story could falter. However, the financial fortress—$735 million in cash, 60% EBITDA margins, aggressive buybacks—provides substantial downside protection while these risks resolve.
For investors, the critical variables to monitor are: (1) pharma client budget releases during the upsell season in calendar Q2-Q3 2026, and (2) AI product launch timing and initial revenue traction. Doximity's history of growing at 2x the market rate suggests it will regain share once budgets normalize. The AI tools' 75% weekly retention and 4x weekly query rates indicate genuine physician value creation. If both factors break favorably, Doximity could exit 2026 with double-digit growth reaccelerating and a new AI revenue stream emerging, making the current valuation an attractive entry point for a dominant platform with durable competitive moats.
